Synmosa Biopharma (4114) — Free Cash Flow Generation Index
Synmosa Biopharma (4114) has a Free Cash Flow Generation Index of 0.68x as of December 2025. Free cash flow of NT$126.26 Million represents 1% of operating cash flow (NT$185.72 Million). Explore Synmosa Biopharma (4114) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Synmosa Biopharma Free Cash Flow Generation Index (2015–2025)
Historical FCF Generation Index trend for Synmosa Biopharma across 9 annual periods. For the full cash flow conversion analysis, see 4114 cash flow metrics.
Annual Free Cash Flow Generation for Synmosa Biopharma (2015–2025)
Year-by-year Free Cash Flow Generation Index for Synmosa Biopharma. Check Synmosa Biopharma total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (TWD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.32x | NT$130.44 Million | NT$411.57 Million | NT$281.13 Million | ▼ -51.6% |
| 2024 | 0.65x | NT$510.97 Million | NT$780.62 Million | NT$269.65 Million | ▲ +38.4% |
| 2023 | 0.47x | NT$242.16 Million | NT$511.93 Million | NT$269.77 Million | ▼ -33.1% |
| 2022 | 0.71x | NT$445.92 Million | NT$630.25 Million | NT$129.29 Million | ▲ +4.0% |
| 2021 | 0.68x | NT$302.17 Million | NT$444.29 Million | NT$93.06 Million | ▲ +124.1% |
| 2020 | 0.30x | NT$77.20 Million | NT$254.40 Million | NT$154.41 Million | ▲ +101.4% |
| 2018 | -21.89x | NT$-350.16 Million | NT$16.00 Million | NT$314.43 Million | ▼ -883.9% |
| 2016 | 2.79x | NT$660.40 Million | NT$236.48 Million | NT$423.92 Million | ▼ -83.2% |
| 2015 | 16.65x | NT$392.86 Million | NT$23.60 Million | NT$369.26 Million | — |